iBio, Inc.
No enriched coverage for $IBIO in the last 7 days.
No SEC Form 4 filings for $IBIO in the last 30 days.
See all $IBIO insider activity →Analysts cut iBio Inc.'s 12-month price target from $5.69 to $5.53, with forecasts ranging from $4.2 to $7. The new target implies 447% upside from the Oct. 7 closing price. All 8 analysts maintain a 'Buy' rating.
H.C. Wainwright initiated coverage on iBio Inc. (NASDAQ:IBIO) with a buy rating and a $7.00 price target, citing potential in its obesity and diabetes treatments. The stock has declined 52% over six months. The firm highlighted the company's cash position of $88.0 million as of June 30, 2026, with runway extending into 2028, despite high cash burn.
iBio Inc. (IBIO) reported a wider net loss of $33.04 million for FY 2026, up from $18.38 million in 2025, due to increased R&D expenses. Revenues fell to $0.10 million from $0.40 million. The company has $88 million in cash. IBIO-600 Phase 1 trial for obesity showed positive data, and IBIO-610 showed promising preclinical results. IBIO stock closed at $1.36, up 2.20% after hours.
Recent IBIO coverage spans financial news, earnings and corporate actions.
Analysts cut iBio Inc.'s 12-month price target from $5.69 to $5.53, with forecasts ranging from $4.2 to $7. The new target implies 447% upside from the Oct. 7 closing price. All 8 analysts maintain a 'Buy' rating.
Analyst upgrade and target raise may drive buying interest.
Earnings miss and higher cash burn increase short‑term downside risk.
The disclosed results highlight a transition to clinical stage and significant cash runway, which may support short‑term price stability and longer‑term upside.
The filing is a management-compensation update tied to a CMO appointment, which can shift near-term sentiment but is not a fundamental operating datapoint.
AlphAI scores every news story that mentions IBIO with an AI model for sentiment and relevance, and aggregates insider trades from iBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts cut iBio Inc.'s 12-month price target from $5.69 to $5.53, with forecasts ranging from $4.2 to $7. The new target implies 447% upside from the Oct. 7 closing price. All 8 analysts maintain a 'Buy' rating.
1 min readH.C. Wainwright initiated coverage on iBio Inc. (NASDAQ:IBIO) with a buy rating and a $7.00 price target, citing potential in its obesity and diabetes treatments. The stock has declined 52% over six months. The firm highlighted the company's cash position of $88.0 million as of June 30, 2026, with runway extending into 2028, despite high cash burn.
1 min readiBio Inc. (IBIO) reported a wider net loss of $33.04 million for FY 2026, up from $18.38 million in 2025, due to increased R&D expenses. Revenues fell to $0.10 million from $0.40 million. The company has $88 million in cash. IBIO-600 Phase 1 trial for obesity showed positive data, and IBIO-610 showed promising preclinical results. IBIO stock closed at $1.36, up 2.20% after hours.
2 min readiBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic an
2 min readiBio, Inc. (IBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer SAN DIEGO, August 4, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesi
2 min readiBio (NASDAQ: IBIO) reported preclinical obese NHP results for its single-dose Activin E antibody IBIO-610. Active Activin E was suppressed in all treated animals through eight weeks, with ~98% reduction at week 4 and ~97% at week 8. In combination with semaglutide, IBIO-610 increased visceral/total fat loss and cut lean-mass loss by 73% versus semaglutide alone; full data will be presented at EASD 2026.
4 min readiBio (NASDAQ: IBIO) said CEO and Chief Scientific Officer Martin Brenner and CFO Felipe Duran will attend the Jefferies Global Healthcare Conference on June 4, 2026 in New York and the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14–15 in Boston. The company will livestream and replay the Jefferies presentation and hold one-on-one investor meetings at Leerink.
2 min readiBio (NASDAQ: IBIO) said it dosed the first participant in a Phase 1 trial of IBIO-600, its first obesity/cardiometabolic program to enter human testing. The randomized, double-blind, placebo-controlled single-ascending-dose study will assess safety, tolerability, PK/PD and body-composition effects in ~32 adults with overweight/obesity, with completion expected in 2H 2027.
4 min readLogos Global Management and its affiliated entities have filed an amended Schedule 13G/A, declaring 0% beneficial ownership of iBio (NASDAQ: IBIO) common stock. The filing, signed on May 15, 2026, indicates that the reporting persons, including Arsani William, beneficially own 0 shares and expressly disclaim group membership and beneficial ownership under Rule 13d-3. This update clarifies their neutral stance and confirms no intent to change or influence control of iBio.
2 min readiBio Inc (IBIO) has released its earnings summary for the quarter that concluded on March 31. The report, distributed by Reuters via TradingView News, provides key financial results for the company during this period. Further details of the earnings report were not included in this brief summary.
2 min read
